Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624672 · ClinicalTrials.gov registry record · Phase 4
Treatment of GLP-1 for Diabetic Bariatric Patients
A Phase 4 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT04624672: Clinical Trial Phase 4 study, sponsored by Geisinger Clinic.
NCT04624672 is a Phase 4 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04624672, a Phase 4 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
Primary Outcome
HbA1C \< 6.5%, fasting glucose \<125 mg/dl, or no medications or active treatment for one year
Interventions
- DRUG Placebo
- DRUG Semaglutide (1 Mg Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 4 |
Why NCT04624672 stopped before completion
NCT04624672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04624672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04624672 about?
NCT04624672 is a clinical study titled "Treatment of GLP-1 for Diabetic Bariatric Patients". This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
What is the current status of trial NCT04624672?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2021-08-25. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT04624672?
The interventions under investigation include: Placebo (DRUG), Semaglutide (1 Mg Dose) (DRUG).
Who is sponsoring clinical trial NCT04624672?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04624672's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI